Skip to main content
Article
Management of adverse events associated with idelalisib treatment: expert panel opinion
Leukemia & Lymphoma (2015)
  • Steven E. Coutré, Stanford University
  • Jacqueline C. Barrientos, Hofstra University
  • Jennifer R. Brown, Harvard University
  • Sven de Vos, University of California, Los Angeles
  • Richard R. Furman, Cornell University
  • Michael J. Keating, University of California, Irvine
  • Daniel Li
  • Susan M. O’Brien, University of California, Irvine
  • John M. Pagel, Cancer Institute
  • Martin H. Poleski, Duke University
  • Jeff P. Sharman, Cancer Institute
  • Nai-Shun Yao
  • Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center
Publication Date
October 3, 2015
DOI
10.3109/10428194.2015.1022770
Citation Information
Steven E. Coutré, Jacqueline C. Barrientos, Jennifer R. Brown, Sven de Vos, et al.. "Management of adverse events associated with idelalisib treatment: expert panel opinion" Leukemia & Lymphoma Vol. 56 Iss. 10 (2015) p. 2779 - 2786
Available at: http://works.bepress.com/john-pagel/53/